• Explore /
  • Poster
  • / Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).

Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).

Abstract Poster

Authors

null

Charlee Nardin

Université de Franche-Comté, Inserm 1098 RIGHT, Besançon, France

Charlee Nardin , Aymeric Hennemann , Kadiatou Diallo , Elisa Funck-Brentano , Eve Puzenat , Valentine Heidelberger , Geraldine Jeudy , Mahtab Samimi , Candice Lesage , Lise Boussemart , Lucie Peuvrel , Sandrine Mansard , Florence Brunet , Emilie Gerard , Alice Seris , Thomas Jouary , Mélanie Saint-Jean , Philippe Saiag , Marc Puyraveau , François Aubin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9529)

DOI

10.1200/JCO.2022.40.16_suppl.9529

Abstract #

9529

Poster Bd #

122

Abstract Disclosures

Similar Posters

Poster

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.

Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.

First Author: Karim Welaya

First Author: Lorenzo Pilla

First Author: Thierry Landre

First Author: Jeremy Aaron Ross